

|   |                                    |                |                            |  |
|---|------------------------------------|----------------|----------------------------|--|
| Form PTO-892<br>U.S. Department of Commerce | Serial Number                      | Group Art Unit | Attachment to Paper Number |  |
|   | 10/681,418                         | 1623           | 02272004                   |  |
| Notice of References Cited                  | APPLICANT(S)<br><br>Shepard et al. |                |                            |  |

### Foreign Patent Documents<sup>†††</sup>


| * |    | DOCUMENT NO.    | DATE     | COUNTRY       | NAME                   | CLASS | SUB-CLASS |  |  |
|---|----|-----------------|----------|---------------|------------------------|-------|-----------|--|--|
| * | L  | W O 95/08556 A1 | 03/30/95 | World(WO/PCT) | Amersham Intl.         | ----- | -----     |  |  |
| * | M  | W O 99/20741 A1 | 04/29/99 | World(WO/PCT) | Geron Corp.            | ----- | -----     |  |  |
| * | N  | W O 96/40708 A1 | 12/19/96 | World(WO/PCT) | La Jolla Pharm. Co     | ----- | -----     |  |  |
| * | O  | W O 96/10300 A1 | 04/04/96 | World(WO/PCT) | Isis Pharm., Inc.      | ----- | -----     |  |  |
| * | P  | W O 94/22483 A2 | 10/13/94 | World(WO/PCT) | D-Pharm Ltd.           | ----- | -----     |  |  |
| * | Q  | W O 96/03151 A2 | 02/08/96 | World(WO/PCT) | Cancer Res. ....       | ----- | -----     |  |  |
| * | AL | W O 96/07431 A1 | 03/14/96 | World(WO/PCT) | U. GA. Res. Fndtn.     | ----- | -----     |  |  |
| * | AM | W O 97/28179 A1 | 08/07/97 | World(WO/PCT) | Regnts U. Calif.       | ----- | -----     |  |  |
| * | AN | GB 982,776      | 02/10/65 | G. Britain    | Wellcome Fndtn         | ----- | -----     |  |  |
| * | AO | W O 01/07454 A1 | 02/01/01 | World(WO/PCT) | Newbiotics, Inc.(I)    | ----- | -----     |  |  |
|   | AP | W O 99/08110 A1 | 02/18/99 | World(WO/PCT) | Newbiotics, Inc. (II)  | ----- | -----     |  |  |
|   | AQ | W O 99/37753 A1 | 07/29/99 | World(WO/PCT) | Newbiotics, Inc. (III) | ----- | -----     |  |  |

### Other References<sup>†††</sup>(Including Author, Title, Date, Pertinent Pages, etc.)

|   |   |   |
|---|---|---|
| * | R | Firestone et al., "A Comparison of the Effects of Antitumor Agents Upon Normal Human Epidermal Keratinocytes and Human Squamous Cell Carcinoma,"<br><i>Journal of Investigative Dermatology</i> , 94(5), 657-661 (May, 1990).                 |
| * | S | Dagle et al., "Targeted Degradation of mRNA in <i>Xenopus</i> oocytes and Embryos Directed by Modified Oligonucleotides: Studies of An2 and Cyclin in Embryogenesis,"<br><i>Nucleic Acids Research</i> , 18(16), 4751-4757 (August 25, 1990). |

† Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

††† References cited by examiner in related cases 10/119,927 and 09/782,721.

|   |          |                                       |
|---|----------|---------------------------------------|
| EXAMINER  | DATE     | page 2 of 3                           |
| L. E. Crane    | 02/26/04 | ¥: Reference not presently available. |
| *A copy of this reference is not being furnished with this office action.<br>(See Manual of Patent Examining Procedure, Section 707.05(a).) |          |                                       |


|   |                                       |                                  |  |  |
|---|---------------------------------------|----------------------------------|--|--|
| Form PTO-892<br>U.S. Department of Commerce | Serial Number<br><b>10/681,418</b>    | Group Art<br>Unit<br><b>1623</b> | Attachment to<br>Paper Number<br><b>02272004</b> |  |
| Notice of References Cited                  | APPLICANT(S)<br><b>Shepard et al.</b> |                                  |  |  |

**Other References** (Including Author, Title, Date, Pertinent Pages, etc.)

|   |           |  |
|---|-----------|--|
| * | <b>T</b>  | <b>Hakimelahi et al.</b> , "Design, Synthesis, and Structure-Activity Relationship of Novel Dinucleotide Analogs as Agents Against Herpes and Human Immunodeficiency Viruses,"<br><i>Journal of Medicinal Chemistry</i> , 38(23), 4648-4659 (November 10, 1995).   |
| * | <b>U</b>  | <b>Naesens et al.</b> , "Anti-HIV Activity and Metabolism of Phosphoramidate Derivatives of D4T-MP with Variations in the Amino Acid Moiety," Poster Session 1, <u>The Tenth International Conference on Antiviral Research</u> , Hotel Nikko, Atlanta, GA, April 6-11, 1997; published in <i>Antiviral Research</i> , 34(2), p. A54 (Abstract 40), (April, 1997). |
| * | <b>V†</b> | <b>Evrard et al.</b> , "An <i>in vitro</i> Nucleoside Analog Screening Method for Cancer Gene Therapy,"<br><i>Cell Biology and Toxicology</i> , 12, 345-350 (1996).  |
| * | <b>W†</b> | <b>Berkow et al. (eds.)</b> , <u>The Merck Manual of Diagnosis and Therapy</u> , 16th Ed., Merck & Co., Rahway, NJ, May, 1992, only page 1278 supplied.  |
| * | <b>X†</b> | <b>Morrison &amp; Boyd (eds.)</b> , <u>Organic Chemistry</u> , Allyn & Bacon, Inc., Boston, MA, 1973, only pages 1170-1180 supplied.   |
| * | <b>Y†</b> | <b>L. B. Townsend (ed.)</b> , <u>Chemistry of Nucleosides and Nucleotides</u> , Volume 3, Plenum Press, New York, NY, 1974, only Table of Contents, Bibliography pages 529-535, and Index pages 537-552 supplied.  |
| * | <b>Z†</b> | <u>The American Heritage College Dictionary, Third Edition</u> , Houghton Mifflin Co., New York, NY, 1997, only page 668 supplied.   |

† Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

††† References cited by examiner in related cases 10/119,927 and 09/782,721.

|   |                         |   |
|---|-------------------------|---|
| EXAMINER<br>L. E. Crane                                  | DATE<br><b>02/26/04</b> | <b>page 3 of 3</b><br>¥: Reference not presently available. |
| *A copy of this reference is not being furnished with this office action.<br>(See Manual of Patent Examining Procedure, Section 707.05(a).) |                         |   |

|   |                                |                |                            |  |
|---|--------------------------------|----------------|----------------------------|--|
| Form PTO-892<br>U.S. Department of Commerce | Serial Number                  | Group Art Unit | Attachment to Paper Number |  |
|   | 10/681,418                     | 1623           | 02272004                   |  |
| Notice of References Cited                  | APPLICANT(S)<br>Shepard et al. |                |                            |  |


**Published U. S. Patent Applications<sup>†††</sup>**

| * |     | DOCUMENT NO.    | DATE     | NAME                 | CLASS | SUBCLASS | Filing Date If Appropriate |
|---|-----|-----------------|----------|----------------------|-------|----------|----------------------------|
| * | P 1 | 2001/0034440 A1 | 10/25/01 | Shepard et al. (I)   | 536   | 026.800  |                            |
| * | P 2 | 2002/0147175 A1 | 10/10/02 | Shepard et al. (II)  | 514   | 049.000  |                            |
| * | P 3 | 2002/0151519 A1 | 10/17/02 | Shepard et al. (III) | 514   | 050.000  |                            |

**U. S. Patent Documents<sup>†††</sup>**

| * |    | DOCUMENT NO. | DATE     | NAME                 | CLASS | SUBCLASS | Filing Date If Appropriate |
|---|----|--------------|----------|----------------------|-------|----------|----------------------------|
| * | A  | 5,212,291 A  | 05/18/93 | Murdock et al. (I)   | 536   | 006.400  |                            |
| * | B  | 5,116,827 A  | 05/26/92 | Murdock et al. (II)  | 514   | 082.000  |                            |
| * | C  | 5,070,082 A  | 12/03/91 | Murdock et al. (III) | 514   | 105.000  |                            |
| * | D  | 5,077,283 A  | 12/31/91 | Murdock et al. (IV)  | 514   | 094.000  |                            |
| * | E  | 5,077,282 A  | 12/31/91 | Murdock et al. (V)   | 514   | 080.000  |                            |
| * | F  | 5,616,564 A  | 04/01/97 | Rapaport et al.      | 514   | 044.000  | 01/07/94                   |
| * | G  | 6,245,750 B1 | 06/12/01 | Shepard (I)          | 514   | 051.000  |                            |
| * | H  | 5,457,187 A  | 10/10/95 | Gmeiner et al.       | 536   | 025.500  |                            |
| * | I  | 5,212,161 A  | 05/18/93 | Moriniere et al.     | 514   | 050.000  |                            |
| * | J  | 3,852,266 A  | 12/03/74 | Kiyanagi et al.      | 536   | 028.550  |                            |
| * | K  | 6,339,151 B1 | 02/15/02 | Shepard et al. (IV)  | 536   | 026.800  |                            |
| * | AA | 6,495,553 B1 | 12/17/02 | Shepard (II)         | 514   | 256.000  |                            |
| * | AB | 6,683,061 B1 | 01/27/04 | Shepard et al. (V)   | 514   | 050.000  |                            |

††† References cited by examiner in related cases 10/119,927 and 09/782,721.

|   |          |                                       |
|---|----------|---------------------------------------|
| EXAMINER  | DATE     | page 1 of 3                           |
| L. E. Crane    | 02/26/04 | ¥: Reference not presently available. |
| *A copy of this reference is not being furnished with this office action.<br>(See Manual of Patent Examining Procedure, Section 707.05(a).) |          |                                       |